Company Overview of Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc., a biotechnology company, develops anti-infective drug candidates. The company offers anti-infective human monoclonal antibodies that target infectious diseases, including nosocomial infections, cystic fibrosis, and severe wound infection. Its products portfolio includes AR-301, a human monoclonal IgG1 antibody that targets staphylococcus aureus alpha-toxin; AR-101 and AR-104, the specific lgM monoclonal antibodies, which target pseudomonas aeruginosa; Aerucin, a human monoclonal IgG1 antibody that targets pseudomonas aeruginosa; Panaecin, an anti-infective for the problem of antibiotic resistance; AR201, a human monoclonal antibody, which treats respiratory sync...
5941 Optical Court
San Jose, CA 95138
Founded in 2003
Key Executives for Aridis Pharmaceuticals, Inc.
Head of Corporate Development
Compensation as of Fiscal Year 2014.
Aridis Pharmaceuticals, Inc. Key Developments
Aridis Pharmaceuticals, Inc. Raises $6.75 Million in Private Placement
Sep 18 14
Aridis Pharmaceuticals, Inc. raised $6.75 million in a private placement, from investors including Nikolaus F. Rentschler.
Aridis Pharmaceuticals LLC Wins $14,527,800 Federal Contract
Sep 24 13
Aridis Pharmaceuticals LLC won a $14,527,800 federal contract from the U.S. Department of Health and Human Services' National Institutes of Health, Bethesda, M.D., for the development of therapeutic medical countermeasures for biodefense and emerging infectious diseases.
Aridis Pharmaceuticals, LLC Presents at 4th Annual OneMedForum New York, Jun-27-2013 12:00 PM
Jun 11 13
Aridis Pharmaceuticals, LLC Presents at 4th Annual OneMedForum New York, Jun-27-2013 12:00 PM. Venue: Metropolitian Club, Morton Room, One East 60(th) Street, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 18, 2014
May 31, 2014